FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3097482947> ?p ?o ?g. }

• W3097482947 endingPage "4521" @default.
• W3097482947 startingPage "4510" @default.
• W3097482947 abstract "Infantile neural ceroid lipofuscinosis (INCL) is a lysosomal storage disorder characterized by mutations in the CLN1 gene that leads to lack of the lysosomal enzyme palmitoyl-protein thioesterase-1 (PPT1), which causes the progressive death of cortical neurons. Enzyme replacement therapy (ERT) is one of the most promising treatments, but its translation toward a clinical use is hampered by the need to deliver the enzyme to the central nervous system and a more detailed understanding of its capability to restore physiologic conditions at the biochemical and protein level, beyond the simple regulation of enzymatic activity. Targeted nanoparticles can promote protein delivery to the central nervous system and affect biological pathways inside cells. Here, we describe an innovative peptide-based stealth nanoparticle that inhibits serum protein adsorption exploiting transferrin-driven internalization to convey the PPT1 enzyme to transferrin receptor-mediated pathways (endocytosis in this work, or transcytosis, in perspective, in vivo). These enzyme-loaded nanoparticles were able to restore stable levels of enzymatic activity in CLN1 patient’s fibroblasts, comparable with the free enzyme, demonstrating that delivery after encapsulation in the nanocarrier does not alter uptake or intracellular trafficking. We also investigate, for the first time, dysregulated pathways of proteome and palmitoylome and their alteration upon enzyme delivery. Our nanoparticles were able of halving palmitoylated protein levels restoring conditions similar to the normal cells. From proteomic analysis, we also highlighted the reduction of the different groups of proteins after treatments with the free or encapsulated enzyme. In conclusion, our system is able to deliver the enzyme to a model of CLN1 disease restoring normal conditions in cells. Investigation of molecular details of pathologic state and enzyme-based correction reveals dysregulated pathways with unprecedented details for CLN1. Finally, we unveil for the first time the dysregulation landscape of palmitoylome and proteome in primary patient-derived fibroblasts and their modifications in response to enzyme administration. These findings will provide a guideline for the validation of future therapeutic strategies based on enzyme replacement therapy or acting at different metabolic levels." @default.
• W3097482947 created "2020-11-09" @default.
• W3097482947 creator A5003384865 @default.
• W3097482947 creator A5015818000 @default.
• W3097482947 creator A5033342633 @default.
• W3097482947 creator A5042723074 @default.
• W3097482947 creator A5057320169 @default.
• W3097482947 creator A5062847907 @default.
• W3097482947 creator A5068237948 @default.
• W3097482947 date "2020-10-28" @default.
• W3097482947 modified "2023-09-26" @default.
• W3097482947 title "Protein Delivery by Peptide-Based Stealth Liposomes: A Biomolecular Insight into Enzyme Replacement Therapy" @default.
• W3097482947 cites W1615667134 @default.
• W3097482947 cites W1964223712 @default.
• W3097482947 cites W1969951885 @default.
• W3097482947 cites W1991823797 @default.
• W3097482947 cites W1996697333 @default.
• W3097482947 cites W2002573954 @default.
• W3097482947 cites W2017077683 @default.
• W3097482947 cites W2018522439 @default.
• W3097482947 cites W2020303641 @default.
• W3097482947 cites W2023863818 @default.
• W3097482947 cites W2025753814 @default.
• W3097482947 cites W2028893730 @default.
• W3097482947 cites W2035543500 @default.
• W3097482947 cites W2050165265 @default.
• W3097482947 cites W2051925512 @default.
• W3097482947 cites W2054043430 @default.
• W3097482947 cites W2058094774 @default.
• W3097482947 cites W2072711133 @default.
• W3097482947 cites W2082984134 @default.
• W3097482947 cites W2083391645 @default.
• W3097482947 cites W2093261118 @default.
• W3097482947 cites W2093306299 @default.
• W3097482947 cites W2101332331 @default.
• W3097482947 cites W2106705861 @default.
• W3097482947 cites W2107128771 @default.
• W3097482947 cites W2110569992 @default.
• W3097482947 cites W2126901292 @default.
• W3097482947 cites W2131028637 @default.
• W3097482947 cites W2135911291 @default.
• W3097482947 cites W2146368604 @default.
• W3097482947 cites W2161946327 @default.
• W3097482947 cites W2163352063 @default.
• W3097482947 cites W2163557498 @default.
• W3097482947 cites W2169589032 @default.
• W3097482947 cites W2191052126 @default.
• W3097482947 cites W2239468677 @default.
• W3097482947 cites W2331701419 @default.
• W3097482947 cites W2335095506 @default.
• W3097482947 cites W2470266050 @default.
• W3097482947 cites W2559342419 @default.
• W3097482947 cites W2575012967 @default.
• W3097482947 cites W2596909879 @default.
• W3097482947 cites W2597562109 @default.
• W3097482947 cites W2669477012 @default.
• W3097482947 cites W2749505036 @default.
• W3097482947 cites W2799850385 @default.
• W3097482947 cites W2808108320 @default.
• W3097482947 cites W2990121996 @default.
• W3097482947 cites W4240059229 @default.
• W3097482947 doi "https://doi.org/10.1021/acs.molpharmaceut.0c00615" @default.
• W3097482947 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33112630" @default.
• W3097482947 hasPublicationYear "2020" @default.
• W3097482947 type Work @default.
• W3097482947 sameAs 3097482947 @default.
• W3097482947 citedByCount "7" @default.
• W3097482947 countsByYear W30974829472021 @default.
• W3097482947 countsByYear W30974829472022 @default.
• W3097482947 countsByYear W30974829472023 @default.
• W3097482947 crossrefType "journal-article" @default.
• W3097482947 hasAuthorship W3097482947A5003384865 @default.
• W3097482947 hasAuthorship W3097482947A5015818000 @default.
• W3097482947 hasAuthorship W3097482947A5033342633 @default.
• W3097482947 hasAuthorship W3097482947A5042723074 @default.
• W3097482947 hasAuthorship W3097482947A5057320169 @default.
• W3097482947 hasAuthorship W3097482947A5062847907 @default.
• W3097482947 hasAuthorship W3097482947A5068237948 @default.
• W3097482947 hasConcept C139770010 @default.
• W3097482947 hasConcept C142724271 @default.
• W3097482947 hasConcept C170493617 @default.
• W3097482947 hasConcept C178790620 @default.
• W3097482947 hasConcept C181199279 @default.
• W3097482947 hasConcept C18150654 @default.
• W3097482947 hasConcept C185350488 @default.
• W3097482947 hasConcept C185592680 @default.
• W3097482947 hasConcept C2779134260 @default.
• W3097482947 hasConcept C2779281246 @default.
• W3097482947 hasConcept C2779820397 @default.
• W3097482947 hasConcept C2779969927 @default.
• W3097482947 hasConcept C28005876 @default.
• W3097482947 hasConcept C55493867 @default.
• W3097482947 hasConcept C71924100 @default.
• W3097482947 hasConcept C86803240 @default.
• W3097482947 hasConcept C95444343 @default.
• W3097482947 hasConceptScore W3097482947C139770010 @default.
• W3097482947 hasConceptScore W3097482947C142724271 @default.
• W3097482947 hasConceptScore W3097482947C170493617 @default.

• next